Related Experiment Video
Updated: Dec 18, 2025

08:07
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.9K
[Vaccine of the future]
Jean-Daniel Lelièvre1,2,3,4
1Vaccine Research Institute, CHU Henri Mondor, 51 avenue Maréchal de Lattre de Tassigny, 94010 Créteil, France.
Revue Francophone Des Laboratoires : RFL
|June 11, 2020
Summary
New vaccine technologies, including nucleic acid vaccines, offer improved efficiency and rapid development against emerging pathogens. These platforms aim for broader protection and faster responses compared to traditional methods.
Area of Science:
- * Immunology and Vaccinology
- * Molecular Biology and Biotechnology
Context:
- * Traditional vaccines (isolation, inactivation, injection) face limitations with new pathogens and require lengthy development.
- * Emerging infectious diseases necessitate rapid, cost-effective vaccine solutions.
- * Protein-based vaccines represent a more recent advancement.
Purpose:
- * To review the evolution of vaccine strategies beyond traditional methods.
- * To highlight the development and potential of nucleic acid-based vaccines (viral vectors, DNA, RNA).
- * To discuss technological advancements in vaccine delivery and antigen characterization.
Summary:
- * Vaccine development has progressed from empirical methods to advanced platforms like viral vectors, DNA, and RNA vaccines.
- * Nucleic acid vaccines utilize antigen-coding sequences for enhanced efficacy and rapid production.
- * Research incorporates reverse vaccinology and targeted delivery systems (e.g., to dendritic cells) for improved vaccine design.
Impact:
- * Development of more efficient and broadly applicable vaccine platforms.
- * Potential for faster response to emerging infectious disease threats.
- * Advancement in targeted vaccine delivery and antigen identification techniques.
More Related Videos
Related Concept Videos
Vaccinations
50.8K
Overview
50.8K
Cancer Vaccines
867
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867
Microorganisms in Medicine and Therapeutics
820
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
820
Immunological Memory
14.6K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
14.6K
Development of Immunocompetence
661
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
661
Cross-reactivity
32.6K
Overview
32.6K

